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Histone deacetylase (HDAC) inhibitors are playing a promising role in lung cancer treatment, and our 
understanding of the mechanisms by which HDAC inhibi-
tors impact lung cancer is evolving. HDAC inhibitors were 
originally identified as a class of drugs that exert epigenetic 
changes by promoting chromatin remodeling and releasing 
transcriptional repression.1 They regulate gene transcription 
through inhibition of histone acetylation but also by alter-
ing structures of nonhistone proteins involved in transcrip-
tion complexes. Mounting evidence indicates the role of 
HDAC inhibitors in transcription-independent mechanisms 
affecting cancer cells.2 These include modulating molecu-
lar chaperones, signal transduction proteins, cytoskeletal 
proteins, regulators of cytoplasmic-nuclear transport, DNA 
repair complexes, and others. HDAC inhibition exerts its 
effect not only on cell proliferation and survival but also on 
angiogenesis and the metastatic potential of cancerous cells. 
HDAC inhibitors can block angiogenesis by inhibiting the 
hypoxia inducible factors and vascular endothelial growth 
factor (VEGF) through mechanisms that are dependent or 
independent of Von Hippel-Lindau (VHL) modulation.3 The 
metastatic potential of cancer cells is gained through tran-
sitioning to a mesenchymal phenotype, a process reversible 
by HDAC inhibitors through the up-regulation of molecules, 
such as E-cadherin. Furthermore, a subclass of HDACi that 
affects HDAC6 regulates HSP90, leading to changes in its 
client proteins such as members of the erythroblastic leuke-
mia viral oncogene homolog (ERBB) family, viral-sarcoma 
(v-Src), AKR mouse thymoma (AKT), and murine leukemia 
viral oncogene homolog 1 (c-RAF).4
The plurality of mechanisms by which HDAC inhibi-
tors affect various processes in cancerous cells drove the 
interest to test their clinical efficacy in lung cancer. Although 
the HDAC inhibitor vorinostat was approved as a single agent 
in the treatment of cutaneous T-cell lymphoma, the major-
ity of the clinical research in lung cancer combined HDAC 
inhibitors with other targeted agents or chemotherapy in an 
effort to augment their efficacy or reverse resistance.5
COMBINATION OF HDAC INHIBITORS WITH 
CYTOTOXIC AGENTS
Several lines of evidence showed the synergistic effect 
of HDAC inhibitors with cytotoxic agents. HDAC inhibitors 
were shown to be synergistic with taxanes in in vitro and in 
vivo modules through the down-regulation of p53, enhancing 
G2/M arrest, and increasing microtubule stability.6 Similarly, 
HDAC inhibitors were shown to augment the effect of carbo-
platin in NSCLC cell lines with wild-type p53 via up-regu-
lation of p21 and enhancing DNA damage. These preclinical 
studies presented the rationale for the combination of HDAC 
inhibitors with chemotherapy in non–small-cell lung cancer 
(NSCLC).7 Ramalingam et al.8 conducted a phase II study 
of carboplatin and paclitaxel with or without vorinostat in 
advanced-stage NSCLC. Grade 4 thrombocytopenia was 
more frequent in patients who received vorinostat (18% ver-
sus 3%; p < 0.05). Patients who had vorinostat experienced 
higher response rate, progression-free survival, and overall 
survival (34% versus 12.5%; p = 0.02; 6.0 versus 4.1 months; 
p = 0.48; 13.0 months versus 9.7 months; p = 0.17). One 
important challenge in combining HDACi with other agents 
is identifying the proper sequence of treatment that would 
lead to the most synergistic outcome. Studies showed that the 
cells arrested at the G1/S checkpoint by cisplatin were more 
sensitive to subsequent treatment with HDAC inhibitors.9 
However, Owonikoko et al.10 showed that vorinostat interacts 
favorably when NSCLC was treated concurrently with carbo-
platin or paclitaxel in NSCLC cells. Vorinostat irreversibly 
increased the expression of γ-H2AX leading to DNA dam-
age, and reversibly increased acetylation of tubulin. These 
findings led to the unique design of the trial introduced by 
Dr. Belani at the IASLC 12th Annual Targeted Therapies of 
Lung Cancer Meeting. One hundred and sixteen patients with 
advanced chemotherapy-naive advanced-stage NSCLC will 
be randomized to receive carboplatin and paclitaxel with or 
without vorinostat. Vorinostat will be given for 4 days start-
ing 2 days before treatment with carboplatin and paclitaxel. 
Vorinostat will be given at escalating dosing, 500 mg, 600 mg, 
and 800 mg, in a run-in portion of the study.
COMBINATION OF HDAC INHIBITORS AND 
DEMETHYLATING AGENTS
Another area of research, pioneered by the group at 
John Hopkins, took advantage of combining two epigenomic 
therapies, HDAC inhibitors and DNA methyltransferase 
inhibitors. This combination is based on extensive preclini-
cal work showing that promoter hypermethylation is a major 
epigenetic event that occurs during lung cancer initiation and 
progression. As an example, hypermethylation of two of any 
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of four genes, CDKN2a, CHD13, APC, or RASSF1a is asso-
ciated with stage I cancer progression and poor survival.11 
Demethylating agents can synergize with HDAC inhibitors 
in reexpressing silenced genes. Jeurgens and colleagues12 
conducted a phase II trial of 5-azacitidine (5AC) and entino-
stat (SNDX-275) in relapsed advanced NSCLC. The patients 
(N = 45) were mainly smokers or former smokers (n = 40) 
who had been heavily pretreated (median of 3 prior thera-
pies). Patients were treated with 5AC 40 mg/m2 administered 
SQ on days 1 to 6 and 8 to 10 with entinostat 7 mg given orally 
on days 3 and 10 of a 28-day cycle. Among the 32 evaluable 
patients, one patient had complete response and was free of 
disease 26 months since enrolment, one patient had partial 
response, nine had stabilization of disease that lasted at least 
12 weeks, and one patient experienced a complete response 
that lasted for 14 months. Four of 19 patients had major 
objective response to subsequent therapies. Interestingly, 
demethylation of the four genes, CDKN2a, CDH13, APC, 
and RASSF1a, detected in serial blood samples was associ-
ated with improved progression-free (p = 0.034) and over-
all survival (p = 0.035). This indicates the potential utility of 
incorporating testing of methylation of those genes to predict 
outcome of patients treated with this combination. Another 
study is evaluating the same combination with entinostat 
given on days 8 and 15. Epigenetic targeted treatment is also 
being evaluated with the combination of 5AC and entinostat 
in stage I disease after curative resection, where patients will 
be randomized to the combination or standard treatment. 
These promising data indicate the role for this unique com-
bination of targeting epigenetics in the treatment of NSCLC.
COMBINATION OF HDACI WITH EPIDERMAL 
GROWTH FACTOR RECEPTOR INHIBITORS
Despite the activity of epidermal growth factor recep-
tor (EGFR) inhibitors in NSCLC, the majority of patients 
progress in their disease. Efforts are ongoing to identify more 
effective EGFR inhibitors or strategies using combination of 
drugs that overcome resistance.5 The rational for the com-
bination of HDACi and EGFRi evolved from several over-
lapping pathways. Dr. Gerber, from the University of Texas 
Southwestern Medical Center, presented one rationale of this 
combination at the IASLC 12th Annual Targeted Therapies of 
Lung Cancer Meeting. Inhibition of mitogen-activated pro-
tein kinases (MAPK) by romidepsin significantly reduced the 
half maximal inhibitory concentration (IC
50
) of erlotinib from 
115 to 0.73 ng/mL in the HCC15 cell line. In contrast, lack of 
inhibition of MAPK by romidepsin in the NSCLC cell-line 
H366 correlated with lack of erlotinib activity. Zhang et al.13 
showed that the combination of romidepsin and erlotinib was 
synergistic in NSCLC cell lines, including those harboring 
KRAS or T790M mutation. Significant inhibition of growth 
of H1299 cell-line xenograft was detected with the combi-
nation of romidepsin and erlotinib as opposed to each drug 
alone (p = 0.04).13
On the basis of these observations, a phase I/II of 
erlotinib and romidepsin in advanced NSCLC was initiated. 
Fourteen patients were enrolled in the romidepsin 8mg/m2 
and 10mg/m2 cohorts. The principal toxicities were nausea 
and vomiting, as five patients had grade 3 toxicities. Among 
the nine initial patients with evaluable disease, five had stable 
disease with duration of 4 to 16 months. The study incorpo-
rates evaluation of skin biopsies for changes in the EGFR 
signaling pathway.
Another strategy to overcome resistance to EGFR 
inhibitors is based on preclinical work that indicates the role 
of up-regulating E-cadherin expression by HDAC inhibitors 
to reverse sensitivity.14 A phase I/II clinical trial enrolled 132 
patients and randomized to erlotinib and entinostat (EE, 67) 
or erlotinib and placebo (EP, 65). In the subset of patients 
with high E-cadherin levels, overall survival was longer in 
the EE group compared with the EP group (9.4 versus 5.4 
months; hazard ratio, 0.35; 95% CI, 0.13–0.92; p = 0.03). 
The adverse event profile was acceptable, with rash, fatigue, 
diarrhea, and nausea the most common adverse events in 
both groups.15
We presented at the IASLC 12th Annual Targeted 
Therapies of Lung Cancer Meeting results of in vivo stud-
ies that indicate using E-cadherin as potential biomarker 
for selecting patients for the combination of EE. When 
entinostat (E; 5 mg/kg) was combined with cetuximab 
(C; 25 mg/kg) in nude mice bearing the E-cadherin posi-
tive A549 xenograft, tumor growth inhibition was higher 
than each drug alone in (C: 65%; E: 70%; E+C: 88%; p = 
0.001) or what is detected in the E-cadherin negative H460 
xenografts (C: 3%, E: 64%, E+C: 75%). We further eval-
uated the activity of EE in the National Cancer Institute 
(NCI)-H1975 and NCI-H1993 cell lines harboring the 
EGFR-L858R/T790M mutation and MET amplification, 
respectively. Synergistic effect was detected when entino-
stat was combined with erlotinib in the NCI-H1975 or NCI-
H1993 cell lines (CI<1).
Results of the preclinical and clinical studies of HDAC 
inhibitors in lung cancer indicate a very promising role for 
this class of drugs. The challenge will be to confirm the appli-
cability of the proposed biomarkers in selecting patients who 
would benefit from combining HDAC inhibitors with cyto-
toxic or other targeted therapies.
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